Patents Examined by Eric Olson
  • Patent number: 11447515
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 20, 2022
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Patent number: 11441118
    Abstract: The present invention provides compositions and methods for transferring phospholipids and other molecules between the leaflets of a cell membrane. The compositions comprise at least one nucleic acid or compound having a hydrophilic region, where the composition is able to form a nanostructure that forms a toroidal pore in a lipid membrane. The nucleic acid or hydrophilic region-containing compound further contains an attached molecule capable of inserting the nanostructure into the lipid membrane. The invention also provides methods for scrambling lipids and other molecules in a cell membrane, which can be used to alter the function of a selected cell or to facilitate the death of the cell. The scrambling activity of synthetic scramblases described herein outperforms previously known enzymatically active DNA nanostructures and naturally occurring scramblases, in some cases by several orders of magnitude.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: September 13, 2022
    Inventors: Aleksei Aksimentiev, Ulrich F. Keyser
  • Patent number: 11440935
    Abstract: Provided are compounds compound according to Formula (I), or a pharmaceutically acceptable salt, solvate, coordination complex or prodrug thereof: wherein, R1 and R2 are independently selected from (C1-C6) alkyl. The compounds have P2X3 receptor or P2X2/3 receptor antagonist activity and are useful for the treatment of diseases and disorders characterized by activation of those receptors.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 13, 2022
    Inventors: Amir Pelleg, Anu Mahadevan, Jie Li, Cynthia Morency
  • Patent number: 11439659
    Abstract: The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: September 13, 2022
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Tatsuya Dokoshi
  • Patent number: 11433045
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 6, 2022
    Inventors: Saskia Kley, Dania Reiche
  • Patent number: 11427611
    Abstract: The present invention relates, in its broadest aspects, to steroidal glycosides useful in the treatment of skin disorders. Particularly, the invention relates to the use of certain steroidal glucosides, per se, or in the form aglycona, derivatives of spirostanol, of its precursor furastanol, or mixtures thereof, used in the treatment of skin disorders, for instance, psoriasis. The invention further relates to formulations containing steroidal glycosides, the process of obtaining extract from the Furcraea foetida plant, and a method of treating skin disorders.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 30, 2022
    Inventors: Lisis Rojo Gomes, Luiz F. Pianowski
  • Patent number: 11419890
    Abstract: Broth compositions prepared from poultry are disclosed. Selected poultry raw materials are processed to obtain a broth having high protein content. Certain specific amino acids are present in relatively higher concentration as compared to home-made broth and other commercial products. The disclosed broth compositions are effective in preventing and/or treating joint diseases and may also provide other nutritional and health benefits.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: August 23, 2022
    Inventors: Roger L. Dake, Stephanie Lynch, Paul L. Durham, Ryan J. Cady, Jordan L. Hawkins
  • Patent number: 11419859
    Abstract: Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 23, 2022
    Inventor: Samuel V. Agresta
  • Patent number: 11396523
    Abstract: The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: July 26, 2022
    Assignees: University of Virginia Patent Foundation, Hampton University
    Inventors: Tyvin A. Rich, Dongfeng Pan, Mahendra D. Chordia
  • Patent number: 11384109
    Abstract: The disclosure discloses a method for separating phenolic acid glucoside compounds from Diaphragma juglandis Fructus, belonging to the technical field of food. The method includes the following steps: (1) extraction: crushing Diaphragma juglandis Fructus, and then extracting by using ethanol to obtain walnut ethanol extract; and (2) separation: performing column chromatography on the walnut ethanol extract obtained in step (1), sequentially eluting by using ethanol of different concentrations, purifying and eluting repeatedly, and performing separation to obtain phenolic acid glucoside compounds. The phenolic acid glucoside compounds are 2-hydroxyl-5-methoxylphenyl-O-?-D-glucopyranoside, 6-hydroxylnaphthyl-1,2-di-O-?-D-glucopyranoside and 2,6-dihydroxynaphthyl-O-?-D-glucopyranoside. Pharmacological experiments confirm that the three compounds have good antioxidant activity.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: July 12, 2022
    Assignee: Jiangnan University
    Inventors: Xiulan Sun, Yida Xu, Deping Xu, Yinzhi Zhang
  • Patent number: 11377469
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 5, 2022
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya
  • Patent number: 11370781
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: June 28, 2022
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Kevin Wayne Kuntz
  • Patent number: 11351184
    Abstract: Disclosed is a preparation of Pulsatilla saponin B4 for injection, comprising Pulsatilla saponin B4 and a pharmaceutically acceptable excipient. The preparation is an aqueous injection or a lyophilized powder injection, more preferably a lyophilized powder injection. Methods for preparing the Pulsatilla saponin B4 aqueous injection and the Pulsatilla saponin B4 lyophilized powder injection comprise dissolution, fluid preparation, filtration and other steps. The preparation of Pulsatilla saponin B4 for injection has a low effective dose for reversing renal injury caused by cisplatin, significantly improves the medication safety of Pulsatilla saponin B4, and is expected to provide a new option for the clinical treatment of renal injuries and renal failure.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 7, 2022
    Inventor: Qi Liu
  • Patent number: 11337994
    Abstract: Described herein are in situ gelling compositions. The compositions include an anti-inflammatory polysaccharide and a gelling polymer, wherein the composition is a liquid prior to administration to a subject but converts to a gel upon administration to the subject. The compositions described herein have numerous applications with respect to the local treatment (reduction or prevention) of inflammation and/or tissue damage.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 24, 2022
    Inventors: Hamidreza Ghandehari, Siam Oottamasathien, Mark Martin Jensen, Joseph Cappello, Wanjian Jia, Glenn D. Prestwich
  • Patent number: 11337991
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 24, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • Patent number: 11339187
    Abstract: The invention comprises a process for the preparation of GalNAc oligonucleotide conjugates which comprises the coupling of a GalNAc cluster compound of the formula or corresponding salts, enantiomers and/or a stereoisomer thereof, with an oligonucleotide in the presence of an O-dicarboximidouronium salt as coupling agent.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: May 24, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Simon Breitler
  • Patent number: 11325936
    Abstract: New 2-deoxy-2,3-dehydro-sialic acids and 2,7-anhydro-sialic acids, which are useful as sialidase inhibitors, and enzymatic methods for preparing them are disclosed. The methods include forming a reaction mixture comprising a glycoside acceptor, a sialic acid donor, and a sialyltransferase; maintaining the reaction mixture under conditions sufficient to form a sialoside; and contacting the sialoside with a Streptococcus pneumoniae sialidase to form the sialic acid product. Methods for the inhibition and sialidases and the treatment of cancer and infectious diseases are also disclosed.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 10, 2022
    Assignee: The Regents of the University of California
    Inventors: Xi Chen, An Xiao, Wanqing Li, Xixuan Li, Yanhong Li, Teri Slack
  • Patent number: 11324776
    Abstract: Maillard reaction products produced by heating carbohydrates with one or more amino acids (e.g., lysine), at basic pH and for a selected reaction time at a particular concentration in solution, can exhibit inhibitory activity against Aggregatibacter actinomycetemcomitans.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 10, 2022
    Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
    Inventor: Raniah Abdulmohsen Afif Jaha
  • Patent number: 11318154
    Abstract: A method of preventing or treating a subject suffering from Clostiridium difficile infection or its associated symptom includes administering a therapeutic effective amount of a HMGB1 inhibitor to the subject. A method of inhibiting toxin-induced cytotoxic effect in colon cells includes contacting the colon cells with an effective amount of a HMGB1 inhibitor.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: May 3, 2022
    Assignees: City University of Hong Kong, Cornell University
    Inventors: Linfeng Huang, Yung-fu Chang, Yingxue Li, Yutian Ren, Wei Xu
  • Patent number: 11311569
    Abstract: An anti-inflammatory combination for improving nutrient metabolisms, intestinal functions and intestinal microecology and an anti-inflammatory food containing the anti-inflammatory combination are disclosed. The anti-inflammatory combination includes inulin, galacto-oligosaccharide, polydextrose, and a water-insoluble dietary fiber. Furthermore, a weight ratio of inulin, galacto-oligosaccharide, polydextrose and water-insoluble dietary fiber is 10-30:5-30:10-40:10-50. The anti-inflammatory food includes cereal flour, and the ratio of the cereal flour to the anti-inflammatory combination is 65-95:35-5. The anti-inflammatory combination is capable of reducing intestinal permeability, blood endotoxins, heavy metals and inflammatory factors, enhancing immunity, improving intestinal microecology and body biochemical indicators, and preventing chronic diseases.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 26, 2022
    Inventors: Bingjun Yang, Mingguo Chi, Wei Bi